Daré Bioscience Q1 net loss narrows as operating expenses fall

Dare Bioscience

14/05/2026 21:15

Overview

US women's health biotech reported Q1 2026 revenue rose to $0.2 mln, net loss narrowed

Operating expenses declined yr/yr due to lower R&D costs and personnel expenses

Company expects first direct product revenue in Q3 2026 with DARE to PLAY and Flora Sync LF5 launches

Outlook

Company expects to begin product revenue from DARE to PLAY in Q3 2026

Flora Sync LF5 revenue expected to begin in June 2026

Revenue from DARE to RECLAIM targeted to begin in 2027

Result Drivers

R&D SERVICES REVENUE - Q1 revenue was mainly from research and development services agreements, not product sales

LOWER R&D COSTS - Operating expenses fell yr/yr, mainly due to lower R&D spending and personnel costs

COMMERCIAL PREPARATIONS - Higher professional services and commercial readiness expenses as company prepares for product launches

Company press release: ID:nGNX9tkHjR

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.20
Q1 Net Income
-$2.99 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dare Bioscience Inc is $10.50, about 269.7% above its May 13 closing price of $2.84

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)